An ATP-site on-off switch that restricts phosphatase accessibility of Akt

Science Signaling

Volumn 5, Issue 223, 2012, Pages

  Lin, Kui ^a   Lin, Jie ^a   Wu, Wen I ^b   Ballard, Joshua ^b   Lee, Brian B ^a   Gloor, Susan L ^b,c   Vigers, Guy P A ^b   Morales, Tony H ^b   Friedman, Lori S ^a   Skelton, Nicholas ^a   Brandhuber, Barbara J ^b  

^a GENENTECH INC   (United States)

^b ARRAY BIOPHARMA INC   (United States)

^c Luca Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ARTICLE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; ALLOSTERISM; BINDING SITE; CHEMICAL STRUCTURE; METABOLISM; PHOSPHORYLATION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; BINDING SITES; MODELS, MOLECULAR; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84860823513     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2002618     Document Type: Article

References (36)

1. D. A. Altomare, J. R. Testa, Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464 (2005).
2. V. Stambolic, J. R. Woodgett, Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol. 16, 461-466 (2006).
3. E. L. Whiteman, H. Cho, M. J. Birnbaum, Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13, 444-451 (2002).
4. P. J. Coffer, J. Jin, J. R. Woodgett, Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335 (Pt. 1), 1-13 (1998).
5. D. R. Alessi, P. Cohen, Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8, 55-62 (1998).
6. J. Yang, P. Cron, V. M. Good, V. Thompson, B. A. Hemmings, D. Barford, Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9, 940-944 (2002).
7. J. Yang, P. Cron, V. Thompson, V. M. Good, D. Hess, B. A. Hemmings, D. Barford, Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 9, 1227-1240 (2002).
8. V. Calleja, D. Alcor, M. Laguerre, J. Park, B. Vojnovic, B. A. Hemmings, J. Downward, P. J. Parker, B. Larijani, Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol. 5, e95 (2007).
9. W. I. Wu, W. C. Voegtli, H. L. Sturgis, F. P. Dizon, G. P. Vigers, B. J. Brandhuber, Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 5, e12913 (2010).
10. Y. Liu, N. S. Gray, Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364 (2006).
11. S. K. Pal, K. Reckamp, H. Yu, R. A. Figlin, Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs 19, 1355-1366 (2010).
12. C. Cherrin, K. Haskell, B. Howell, R. Jones, K. Leander, R. Robinson, A. Watkins, M. Bilodeau, J. Hoffman, P. Sanderson, G. Hartman, E. Mahan, T. Prueksaritanont, G. Jiang, Q. B. She, N. Rosen, L. Sepp-Lorenzino, D. Defeo-Jones, H. E. Huber, An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol. Ther. 9, 493-503 (2010).
13. E. K. Han, J. D. Leverson, T. McGonigal, O. J. Shah, K.W.Woods, T. Hunter, V. L. Giranda, Y. Luo, Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26, 5655-5661 (2007).
14. N. Rhodes, D. A. Heerding, D. R. Duckett, D. J. Eberwein, V. B. Knick, T. J. Lansing, R. T. McConnell, T. M. Gilmer, S. Y. Zhang, K. Robell, J. A. Kahana, R. S. Geske, E. V. Kleymenova, A. E. Choudhry, Z. Lai, J. D. Leber, E. A. Minthorn, S. L. Strum, E. R. Wood, P. S. Huang, R. A. Copeland, R. Kumar, Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366-2374 (2008).
15. T. Okuzumi, D. Fiedler, C. Zhang, D. C. Gray, B. Aizenstein, R. Hoffman, K. M. Shokat, Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484-493 (2009).
16. K. Lin, GDC-0068: A novel, selective, ATP-competitive inhibitor of Akt, in Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2 to 6 April 2011. Abstract DDT02-01.
17. B. D. Manning, Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167, 399-403 (2004).
18. J. R. Bayascas, D. R. Alessi, Regulation of Akt/PKB Ser473 phosphorylation. Mol. Cell 18, 143-145 (2005).
19. J. R. Bencsik, D. Xiao, J. F. Blake, N. C. Kallan, I. S. Mitchell, K. L. Spencer, R. Xu, S. L. Gloor, M. Martinson, T. Risom, R. D. Woessner, F. Dizon, W. I. Wu, G. P. Vigers, B. J. Brandhuber, N. J. Skelton, W. W. Prior, L. J. Murray, Discovery of dihydrothienoand dihydrofuropyrimidines as potent pan Akt inhibitors. Bioorg. Med. Chem. Lett. 20, 7037-7041 (2010).
20. J. F. Blake, N. C. Kallan, D. Xiao, R. Xu, J. R. Bencsik, N. J. Skelton, K. L. Spencer, I. S. Mitchell, R. D.Woessner, S. L. Gloor,T. Risom, S. D. Gross, M. Martinson, T. H. Morales, G. P. Vigers, B. J. Brandhuber, Discovery of pyrrolopyrimidine inhibitors of Akt. Bioorg. Med. Chem. Lett. 20, 5607-5612 (2010).
21. T. Gao, F. Furnari, A. C. Newton, PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18, 13-24 (2005).
22. M. T. Bilodeau, A. E. Balitza, J. M. Hoffman, P. J. Manley, S. F. Barnett, D. Defeo-Jones, K. Haskell, R. E. Jones, K. Leander, R. G. Robinson, A. M. Smith, H. E. Huber, G. D. Hartman, Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg. Med. Chem. Lett. 18, 3178-3182 (2008).
23. D. D. Sarbassov, D. A. Guertin, S. M. Ali, D. M. Sabatini, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
24. D. P. Sutherlin, D. Sampath, M. Berry, G. Castanedo, Z. Chang, I. Chuckowree, J. Dotson, A. Folkes, L. Friedman,R. Goldsmith, T. Heffron, L. Lee, J. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, W. W. Prior, L. Salphati, S. Sideris, Q. Tian, V. Tsui, N. C. Wan, S.Wang, C.Wiesmann, S. Wong, B. Y. Zhu, Discovery of (thienopyrimidin-2- yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J. Med. Chem. 53, 1086-1097 (2010).
25. R. I. Feldman, J. M. Wu, M. A. Polokoff, M. J. Kochanny, H. Dinter, D. Zhu, S. L. Biroc, B. Alicke, J. Bryant, S. Yuan, B. O. Buckman, D. Lentz, M. Ferrer, M. Whitlow, M. Adler, S. Finster, Z. Chang, D. O. Arnaiz, Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 280, 19867-19874 (2005).
26. J. Zhou, J. A. Adams, Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase. Biochemistry 36, 15733-15738 (1997).
27. 2+ during rate-limiting ADP release from protein kinase A. Biochemistry 48, 11532-11545 (2009).
28. A. Kowluru, S. A. Metz, Purine nucleotide- and sugar phosphate-induced inhibition of the carboxyl methylation and catalysis of protein phosphatase-2A in insulin-secreting cells: Protection by divalent cations. Biosci. Rep. 18, 171-186 (1998).
29. C. W. Lindsley, Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber, M. E. Duggan, Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761-764 (2005).
30. J. D. Carpten, A. L. Faber, C. Horn, G. P. Donoho, S. L. Briggs, C. M. Robbins, G. Hostetter, S. Boguslawski, T. Y. Moses, S. Savage, M. Uhlik, A. Lin, J. Du, Y. W. Qian, D. J. Zeckner, G. Tucker-Kellogg, J. Touchman, K. Patel, S. Mousses, M. Bittner, R. Schevitz, M. H. Lai, K. L. Blanchard, J. E. Thomas, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-444 (2007).
31. C. J. Green, O. Goransson, G. S. Kular, N. R. Leslie, A. Gray, D. R. Alessi, K. Sakamoto, H. S. Hundal, Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J. Biol. Chem. 283, 27653-27667 (2008).
32. M. J. Lindhurst, J. C. Sapp, J. K. Teer, J. J. Johnston, E. M. Finn, K. Peters, J. Turner, J. L. Cannons, D. Bick, L. Blakemore, C. Blumhorst, K. Brockmann, P. Calder, N. Cherman, M. A. Deardorff, D. B. Everman, G. Golas, R.M. Greenstein, B.M. Kato, K. M. Keppler-Noreuil, S. A. Kuznetsov, R. T. Miyamoto, K. Newman, D. Ng, K. O'Brien, S. Rothenberg, D. J. Schwartzentruber, V. Singhal, R. Tirabosco, J. Upton, S. Wientroub, E. H. Zackai, K. Hoag, T. Whitewood-Neal, P. G. Robey, P. L. Schwartzberg, T. N. Darling, L. L. Tosi, J. C. Mullikin, L. G. Biesecker, A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365, 611-619 (2011).
33. Collaborative Computational Project, Number 4, The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
34. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
35. M. Valcu, C. M. Valcu, Data transformation practices in biomedical sciences. Nat. Methods 8, 104-105 (2011).
36. T. O. Chan, J. Zhang, U. Rodeck, J. M. Pascal, R. S. Armen, M. Spring, C. D. Dumitru, V. Myers, X. Li, J. Y. Cheung, A. M. Feldman, Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc. Natl. Acad. Sci. U.S.A. 108, E1120-E1127 (2011).